PATENT CLAIM ANALYSIS

Application Number: 16253077
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["424", "133100"]

Abstract:
The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

Claim (Index 19):
A method for the treatment of anthrax disease comprising administering to a patient a therapeutically effective amount of a pharmaceutical preparation comprising a monoclonal antibody that binds anthrax protective antigen (PA) and a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 99.0
- Lexical Diversity: 1.88235
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11793735', '14031508', '12528427', '13310463', '14181099']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7892341493911732
- 35 USC 102 Novelty (BERT): 0.5747574579711542
- Combined Prediction Score: 0.7677864802491714
- Mean Citation Score: 449.78025400000007
- Max Citation Score: 516.8979
- Similarity Product: 383.36761032178407

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test